Post written by: BioTech Health X
You May Also Like
FDA Delays Moderna RSV Vaccine Decision
- BioTech Health X
- May 13, 2024
- 5 minute read
Table of Contents Hide Key Features of mRNA-1345Market Size for Moderna’s RSV Vaccine Potential Moderna’s RSV vaccine, mRNA-1345,…
Novartis Pioneers RNA Therapeutics with Borealis Biosciences for Kidney Diseases
- BioTech Health X
- August 22, 2024
- 4 minute read
Introduction In a groundbreaking move for the biotech industry, Novartis has partnered with Versant Ventures to establish Borealis…
EF Hutton Initiates Coverage of Cel-Sci (CVM) with $17 Price Target Ahead of Rumored News
- BioTech Health X
- April 7, 2022
- 5 minute read
Table of Contents Hide About Cel-Sci CorporationEF Hutton Analyst Tim Moore Coverage of Cel-SciEF Hutton Key Points for…
Allay Therapeutics Appoints New Chief Medical Officer
- BioTech Health X
- July 8, 2021
- 2 minute read
David Hewitt, M.D. Appointed as New Allay Therapeutics Chief Medical Officer Clinical-stage biotechnology company Allay Therapeutics recently announced…
Krystal Biotech Announces FDA IND Acceptance for KB407 Cystic Fibrosis Clinical Trial
- BioTech Health X
- August 1, 2022
- 3 minute read
Table of Contents Hide About Krystal Biotech’s KB407KB407 Phase 1 Trial OverviewCystic Fibrosis OverviewAbout Krystal Biotech, Inc. Leader…
Merck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial
- BioTech Health X
- July 20, 2022
- 3 minute read
Today Merck & Co. (NYSE: MRK) announced that Keytruda has failed the Phase 3 clinical trial KEYNOTE-412 evaluating…